Clozapine Versus “High-Dose” Olanzapine in Refractory Early-Onset Schizophrenia: An Open-Label Extension Study

Abstract

Objective: A recent 12-week controlled comparison demonstrated the superiority of clozapine to "high-dose" olanzapine in adolescents with treatment-refractory schizophrenia. In the present study, the authors conducted a 12-week, open-label, follow-up study to examine changes in lipid and glucose metabolism in youths maintained on clozapine and to determine whether patients who were previously randomized to high-dose olanzapine (up to 30 mg/day) responded to clozapine. Method: Thirty three (14 clozapine, 19 olanzapine) (85%) of 39 patients were available for the present 12-week, open-label extension study. Extended safety data using an intention-to-treat analysis from the 14 subjects treated with clozapine for a total of 24 weeks are presented. In addition, we report the clinical outcomes for 10 of 19 olanzapine-treated patients who were switched after 12 weeks to clozapine due to treatment nonresponse. Clinical response was defined as a decrease of 30% or more in total Brief Psychiatric Rating score from week 12 and a Clinical Global Impression-Improvement rating of 1 (very much improved) or 2 (much improved). Results: The incidence of hypertriglyceridemia (defined as fasting triglycerides Ͼ125 mg/dL) (10/14 ϭ 71%) and the incidence of "prediabetes" (defined as fasting blood glucose Ն100) (4/14 ϭ 29%) at week 24 in the clozapine-treated subjects were notable. Seven (70%) of 10 of young patients with schizophrenia who failed treatment with "high-dose" olanzapine were found to respond to a 12-week, open-label clozapine trial. Conclusions: Clinicians and caregivers need to be aware of potential metabolic adverse events of long-term clozapine treatment. Adolescents with a poor response to olanzapine may do better on clozapine. 307

Identification and counseling for obesity among children on psychotropic medications in ambulatory settings

“…The criteria align with recognized definitions for overweight and obesity in children (19). The excess weight gain noted with psychotropic medications is associated with an increased risk for hyperglycemia, insulin resistance, exacerbation or onset of diabetes, elevated triglycerides and cholesterol levels (7,8,(29)(30)(31)(32)(33). Other associated conditions of obesity include low selfesteem, which increases the likelihood of high-risk behaviors that can worsen underlying mental health conditions (11).…”

“…A troublesome side effect of many of these medications is weight gain (4,(6)(7)(8). Children can gain as much as 4-10 kg in a 10-week period (6).…”

Missed Diagnosis of Tardive Dystonia in an Adolescent Girl Treated with Risperidone

“…In comparison, rates of neurological side effects with quetiapine are no different from placebo (DelBello et al 2002(DelBello et al , 2009Connor et al 2008). Neurological side effects from clozapine were not encountered in randomized trials comparing it with olanzapine (Shaw et al 2006;Kumra et al 2008) and haloperidol (Kumra et al 1996). Data on neurological complications with ziprasidone in children are scarce; one placebo-controlled trial described akathisia in 1 of 16 subjects randomized to ziprasidone therapy (Sallee et al 2000).…”

High-Dose Neuroleptics and Neuroleptic Rotation for Agitated Delirium Near the End of Life

“…12 However, our use of olanzapine 280 mg/d exceeds by nearly 10 times the maximum of 30 mg/d employed in 1 recent study of ''high-dose'' olanzapine in schizophrenia. 13 Hospice and palliative care practitioners should be familiar with substantial dose escalation of medication dosage when justified by the presence of refractory symptoms. Certainly, opiates are administered at extraordinarily high doses near the end of life when pain is refractory to standard doses, and the primary goal of treatment is comfort.…”